// App-Quantinova.ai

278 : The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA

Researchers

Presenter

  • Patrick Durez

Principal Investigators

  • Eugen Feist

  • Ricardo Blanco

  • Vijay Rajendran

  • Nadia Verbruggen

  • Katrien Van Beneden

  • James Galloway

Medical Centers

  • Institute de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc - Université Catholique de Louvain (UCL), Brussels, Belgium

  • Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Galapagos NV, Gent, Belgium

  • Galapagos, Mechelen, Belgium

  • Kings College London, London, United Kingdom

Locations

  • Belgium

  • Germany

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Infectious Diseases (ID)

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Shingles

  • Skin carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT02065700

  • NCT03025308

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved